ART begins SoftScan trial at UCSD

AuntMinnie.com staff writers
Mar 29, 2006

Canadian optical molecular imaging developer ART Advanced Research Technologies has initiated clinical trials of its SoftScan optical breast imaging system at the Moores Cancer Center at the University of California, San Diego.

The trial will be part of ART's North American pivotal study for SoftScan, according to the Saint-Laurent, Quebec-based vendor.

By AuntMinnie.com staff writers
March 30, 2006

Related Reading

ART begins Princess Margaret trial, March 22, 2006

ART posts sales gains in Q4, but loss widens, March 10, 2006

ART to buy Alerion, February 15, 2006

ART begins SoftScan study in western Canada, November 24, 2005

ART sales increase in Q3, November 3, 2005

Copyright © 2006 AuntMinnie.com

Latest in Molecular Imaging
A Dpatient
New criteria released for amyloid and tau PET imaging
January 8, 2025
New! Imaging Life Issue 20 now available
Sponsored
New! Imaging Life Issue 20 now available
January 1, 2025
Prostate Imaging2
PSMA-PET imaging spiked after FDA approval
January 6, 2025
Prostate Cancer
PSMA-PET/CT bests conventional imaging for prostate cancer diagnosis
January 3, 2025
Related Stories
187x200 Am Logo
Companies
AuntMinnie.com
2006 03 29 15 57 47 706
Molecular Imaging
MRI, PET disclose neurological decline in preclinical Huntington's disease
2006 02 22 17 06 07 706
Molecular Imaging
Rubidium-based PET may finally get its due
New! Imaging Life Issue 20 now available
Sponsor Content
New! Imaging Life Issue 20 now available
More in Molecular Imaging
New criteria released for amyloid and tau PET imaging
By Will Morton
New appropriate use criteria for amyloid and tau PET imaging of amyloid and tau pathology has been released.
January 8, 2025
A Dpatient
PET scans can reduce lymph node procedures
By Will Morton
Negative prostate-specific antigen (PSMA) PET scans can be used to avoid unnecessary pelvic lymph node dissection in certain prostate cancer patients undergoing radical prostatectomies.
January 7, 2025
Psma Pet
PSMA-PET imaging spiked after FDA approval
By Will Morton
Rates of PET prostate cancer imaging increased rapidly after its approval by the U.S. Food and Drug Administration (FDA).
January 6, 2025
Prostate Imaging2
PSMA-PET/CT bests conventional imaging for prostate cancer diagnosis
By Kate Madden Yee
PSMA-PET/CT bests conventional imaging when it comes to identifying high-risk, nonmetastatic, hormone-sensitive prostate cancer, researchers say.
January 3, 2025
Prostate Cancer
Kidneys appear to tolerate Lu-177 treatments
By Will Morton
Kidney-absorbed doses of lutetium-177 (Lu-177)-based treatments for prostate cancer and neuroendocrine tumors appear to be below toxicity thresholds.
December 19, 2024
Kidneys
African American men respond more favorably to Ra-223 therapy
By Will Morton
African American men with metastatic castrate-resistant prostate cancer may respond more favorably than white men to treatment with radium-223.
December 17, 2024
Prostate Imaging
PET visualizes acute graft vs. host disease
By Will Morton
F-18 fluorothymidine PET can identify early acute gastrointestinal graft versus host disease after patients undergo bone marrow transplants.
December 16, 2024
F-18 FLT-PET imaging of gastrointestinal GVHD. Examples of F-18 FLT uptake in a participant with no GVHD (left) and a participant with acute GVHD and uptake in the jejunum and ileum (right). Arrows denote increased uptake in the GI tract. Image available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of RSNA.
Immuno-PET tracer shows promise in patients with liver cancer
By Will Morton
A new PET radiotracer has the potential for visualizing responses in liver cancer patients undergoing immunotherapy.
December 12, 2024
PET/CT images of F-18 AlF-NOTA-BCP137 in patients with hepatocellular carcinoma (HCC) and immunofluorescence analysis of patient tissues. (A) F-18 AlF-NOTA-BCP137 PET/CT images before and after immunotherapy for patient 1 and patient 2. (B) F-18 AlF-NOTA-BCP137 PET/CT and MR images of patient 3 (left panels) after one cycle of immunotherapy. PET images showed higher uptake by tumor and spleen, and PET result was evaluated as positive; therefore, the patient was considered to be responder to treatment and underwent surgical resection. Representative images of hematoxylin and eosin (HE) staining and multiplex immunofluorescence of CD8 and CD137 (right panels) in HCC tumor and adjacent normal tissues of patient 3 after surgery. Nuclei were stained with 4′,6-diamidino-2-phenylindole. Primary tumors are indicated by white arrows, and increased thyroid uptake is indicated by red arrow in PET images. Image courtesy of the Journal of Nuclear Medicine.
MGH's Mahmood named new RSNA president
By AuntMinnie.com staff writers
Mahmood's primary research for the past 30 years has been in molecular imaging and its application to guide precision medicine.
December 6, 2024
Rsna Mahmood Thumbnail
New SPECT-based coronary risk score developed for women
By Will Morton
A new risk score based on SPECT imaging and other variables can accurately predict risks for women of major adverse cardiovascular events.
December 6, 2024
Heart Infection
PET/CT superior to CT in detecting bone metastases
By Will Morton
F-18 FDG-PET/CT performs better and is more cost-effective than CT in determining biopsy sites for suspected bone metastases.
November 26, 2024
Cancer
PET scan times can be reduced in Alzheimer’s patients
By Will Morton
F-18 florbetaben PET scans for diagnosing Alzheimer’s disease can be reduced from 20 minutes to five minutes without losing accuracy.
November 25, 2024
Patient Elderly Confused Headache
Page 1 of 599
Next Page